Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both ...

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

HCA Healthcare UK is offering amyloid-targeting therapies for patients with early-stage Alzheimer’s disease.

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness.

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...

The rapid influx of new medications brought to market over the past decade has revolutionized health care by offering new ...

A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Asceneuron is the latest biotech to face setbacks in developing tau-targeting therapies for Alzheimer’s. After Eli Lilly and ...

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia TOKY ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...